Reported Earlier, Vir Biotechnology Announces Phase 2 Data Showing Tobevibart And Elebsiran Combination Achieves 66% Undetectable HDV RNA At Week 48 With Favorable Safety

Vir Biotechnology +0.67%

Vir Biotechnology

VIR

9.02

+0.67%

  • SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48
  • Combination well-tolerated: No grade 3 or higher treatment-related adverse events and no treatment-related discontinuations
  • ECLIPSE registrational program evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta fully underway, with topline data expected in the first quarter of 2027
  • Data presented at AASLD The Liver Meeting® and simultaneously published in the New England Journal of Medicine
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.